spacer
home > ebr > summer 2018 > alternative approaches
PUBLICATIONS
European Biopharmaceutical Review

Alternative Approaches

Novel cancer therapies extend far beyond traditional chemo- and radiotherapy approaches. Specific small-molecule inhibitors or antibodies targeting epitopes at the surface of cancer cells are employed to fight cancer cells. Antibody-drug conjugates deliver toxic or radioactive compounds directly to the tumour cell, and bispecific antibodies present tumour cells to the immune system. Even more advanced immune therapies such as CAR-T techniques boost the immune system by modifying T-cells. Stem cell and gene editing-based therapies are getting off the starting blocks, raising hopes towards more effective and safer cancer therapies.

Despite their structural and molecular diversity, these novel therapies have one thing in common: unlike conventional therapies, which attack every fast-dividing cell, they aim to specifically target features unique to tumour cells, allowing the use of highly potent therapies while minimising side effects on healthy tissue. Therefore, identification and characterisation of target structures is a prerequisite to the success of novel cancer therapies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Ute Boronowsky is a freelance science and marketing writer, translator, and journalist, covering topics relevant to the biotech and pharma industry. She received a PhD in biochemistry from the University of Bochum, Germany, did post-doctoral research in biochemistry at UCLA, US, and holds a degree in science journalism from the mibeg Institute for Media in Cologne, Germany. Ute has more than 15 years working experience from sales and marketing positions in the biotech industry and is co-founder of the start-up company Cube Biotech. She is member of the Chartered Institute of Linguists, UK, and of the Science Inbound writer’s network.
spacer
Dr Ute Boronowsky
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement